Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study.
Lu S, Wu L, Wang Q, Wang Z, Lv D, Ma R, Zhu B, van Tran N, Jiang L, Nan K, Laktionov K, Clarke S, Song M, Mann H, Liu Y, Shi X, Wu YL; PEARL investigators.
Lu S, et al. Among authors: wu yl.
J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02433-X. doi: 10.1016/j.jtho.2024.10.024. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 39521433